Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis
Public ClinicalTrials.gov record NCT03710291. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis
Study identification
- NCT ID
- NCT03710291
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Tricida, Inc.
- Industry
- Enrollment
- 1,480 participants
Conditions and interventions
Conditions
Interventions
- TRC101 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 19, 2018
- Primary completion
- Aug 22, 2022
- Completion
- Sep 26, 2022
- Last update posted
- Oct 13, 2022
2018 – 2022
United States locations
- U.S. sites
- 20
- U.S. states
- 9
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site 4136 | Azusa | California | 91702 | — |
| Investigative Site 4148 | Denver | Colorado | 80230 | — |
| Investigative Site 4157 | Boca Raton | Florida | 33431 | — |
| Investigative Site 4146 | Bradenton | Florida | 34209 | — |
| Investigative Site 4102 | Coral Springs | Florida | 33071 | — |
| Investigative Site 4153 | Fort Lauderdale | Florida | 33308 | — |
| Investigative Site 4122 | Hollywood | Florida | 33021 | — |
| Investigative Site 4123 | Hollywood | Florida | 33024 | — |
| Investigative Site 4104 | Miami | Florida | 33015 | — |
| Investigative Site 4130 | Miami Lakes | Florida | 33014 | — |
| Investigative Site 4116 | Port Charlotte | Florida | 33952 | — |
| Investigative Site 4152 | Tampa | Florida | 33637 | — |
| Investigative Site 4127 | Augusta | Georgia | 30904 | — |
| Investigative Site 4141 | Greenbelt | Maryland | 20770 | — |
| Investigative Site 4155 | Kansas City | Missouri | 64111 | — |
| Investigative Site 4108 | Greenville | North Carolina | 27834 | — |
| Investigative Site 4106 | Kinston | North Carolina | 28504 | — |
| Investigative Site 4107 | New Bern | North Carolina | 28562 | — |
| Investigative Site 4124 | Bethlehem | Pennsylvania | 18017 | — |
| Investigative Site 4132 | Nashville | Tennessee | 37205 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 183 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03710291, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2022 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03710291 live on ClinicalTrials.gov.